Omicron sub-variants BA.4 and BA.5: With respect to Omicron’s sub-variants BA.4 and BA.5, experts have feared that if necessary steps are not taken to prevent the infection, it may lead to other cases. I will also come to the states. , can do that.
Omicron sub-variants BA.4 and BA.5: Coronavirus infection is increasing continuously in the world including India and meanwhile cases of Omicron sub-variants BA.4 and BA.5 have been reported. Omicron’s sub-variants BA.4 and BA.5 have made their knock in India, although it is a matter of relief that so far cases have been reported only in Maharashtra. But, experts have expressed apprehension that if necessary steps are not taken to prevent the infection, then its cases may come up in other states as well.
How dangerous are Omicron’s sub-variants BA.4 and BA.5?
Coronavirus sub-variants BA.4 and BA.5 have raised concerns in some countries, but the risk is low in India. Experts say that all these are variants of Omicron, so their effect will be less visible in India because the immunity against Omicron is already strong among the people of the country. However, there is a need to be cautious about these variants, and monitoring has been increased.
Read More: Corona: 37 lakh new patients in a week, 9 thousand deaths… Omicron’s new threat alert in June.
Different BA.4 and BA.5 Symptoms in People
According to experts, it is critical to monitor the symptoms of infected patients because the symptoms of BA.4 and BA.5 have been observed differently in different people. When infected with Omicron subvariants BA.4 and BA.5, common symptoms such as fever, headache, vomiting, abdominal pain, sore throat, and cough may occur.
What did WHO say about BA.4 and BA.5?
The World Health Organization (WHO) has considered Omicron’s sub-variants BA.4 and BA.5 as mild and not ‘variants of concern’. The WHO says that the symptoms of these two sub-variants are not as severe and neither is as contagious as the previous variants. However, along with this, the World Health Organization has advised that there is a need to monitor its patients in different countries.
